Labelling Harmonization 2011
|
|
- Penelope Perkins
- 6 years ago
- Views:
Transcription
1 Labelling Harmonization 2011 DIA, Bethesda, MD Core Labeling During Clinical Development Su Yueh Lin Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual id presenter and should not be attributed t to Drug Information Association, Inc. ( DIA ), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated. These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. i All rights reserved. Drug Information Association, DIA and DIA logo are registered trademarks or trademarks of Drug Information Association Inc. All other trademarks are the property of their respective owners. Drug Information Association 2 1
2 Topics: Various Core Labeling used during Clinical Development and their interrelationships How early to start and how and when to transition to core labeling for a development product Benefits of applying the principles of core labeling during clinical development Drug Information Association 3 Topics: Various Core Labeling used during Clinical Development and their interrelationships How early to start and how and when to transition to core labeling for a development product Benefits of applying the principles of core labeling during clinical development Drug Information Association 4 2
3 The CIOMS Working Group V proposes that the IB contain a section identical in structure to the Company Core Safety Information that is included in the Company Core Data Sheet for a marketed product, and that it be referred to as the Development Core Safety Information (DCSI). This would satisfy the need to help investigators and sponsors more effectively by presenting and updating a focused, dedicated Development Core Safety Information section that can conveniently be placed within the IB, perhaps as an Appendix. Furthermore, it is proposed that the DCSI develop into the CCSI that is included in the first Company Core Data Sheet for the product's entry into the market. [CIOMS working group V] Drug Information Association 5 During drug development, companies may have a variety of labeling related tools to Facilitate drug development with target labeling in mind Align desired marketing and labeling objectives with development program design (study design) Examples of these labeling tools during drug development (with no standard terminology): Investigator Brochure (IB) Target Labeling (TL)/ Target Profile Development Core Data Sheet () Development Core Safety Information (DCSI) CIOMS V FDA Target Product Profile (TPP) Others Drug Information Association 6 3
4 Types of Core Labeling during Clinical Development - IB vs CCDS IB CCDS Investigator s Brochure is the Predecessor of the CCDS Both IB and CCDS Represent Company s view of a product and its safety profile Are internal documents shared with external persons/institutions but are not fully public Are with multi-nation/region approach Drug Information Association 7 Types of Core Labeling during Clinical Development Development Core Data Sheet () vs Target Labeling (TL) IB CCDS TL (Development Core Data Sheet) for development labeling TL (Target Labeling)/Target Profile set of living objectives for the development team Both and TL are internal documents do not follow external format requirement Drug Information Association 8 4
5 Types of Core Labeling during Clinical Development Target Product Profile (TPP) and Draft SmPC IB TL TPP dsmpc TPP dsmpc CCDS TPP: FDA Target Product Profile dsmpc: Draft SmPC Both TPP and dsmpc are for discussion with Regulatory Agencies are based on and TL can follow FDA TPP format and EU SmPC format Drug Information Association 9 Types of Core Labeling during Clinical Development Development Core Safey Information (DCSI) vs Company Core Safety Information (CCSI) IB CCDS DCSI CCSI DCSI contains a set of evolving safety information including Expected events Anticipated events CI, W&P etc. CCSI contains a set of established safety information including ADRs/ IAs Anticipated ADRs/ IAs CI, W&P etc. IA: Interaction CI: Contraindication ADR: Adverse Drug Reaction W&P: Warnings and Precautions Drug Information Association
6 DCSI and CCSI See presentation in session 2, The Adverse Reactions and Interactions ti Section of a CCDS for definitions iti of adverse event or adverse reaction and the expectedness for safety reporting and labeling. Drug Information Association 11 Format and features of - example
7 Format and features of - example The format of the can be customized to accommodate the specific needs for a development project can contain, at the same time, the target and confirmed context, and anticipated local deviations 13 Topics: Various Core Labeling used during Clinical Development and their interrelationships How early to start and how and when to transition to core labeling for a development product Benefits of applying the principles of core labeling during clinical development Drug Information Association
8 When to start with a Development Labeling IB Pre-clin. PK First safety TL CCDS Early compound Phase1 Phase2 Phase3 Study results Phase3 Submission 15 Core Labeling Team Pharmacokinetics Pre-clinical Toxicology Global Pharmacovigilance and Epidemiology Clinical Quality Assurance Drug Regulatory Affairs (including CMC) * Control of CDS in one Labeling department or in Regulatory Medical Affairs and Marketing Legal 16 8
9 From to CCDS to Local Labeling When to start with a development labeling As soon as possible, as this can be used for agency discussions. US: Target Product Profile EU: Draft SmPC When to start drafting local labeling At some point of time add, at least, USPI and EU SmPC Depends on Project team but generally months before submission CCDS stays company opinion CCDS can be used to develop proposed USPI and EU SmPC, and keep them in line 17 From to CCDS to Local Labeling TL CCDS Interface Labeling Deliverables Pre-IND EOP*1 EOP2A EOP2/ Pre-Phase 3 Process Phase 3 CCDS Pre- NDA/BLA USPI SmPC Target Labeling Process *EOP: end of phase 18 9
10 From to CCDS to Local Labeling As early as possible Approx. 18 months US-PI CCDS EU- SmPC Internal approval Submission FDA Submission EMEA 19 From to CCDS to Local Labeling Early Phase(s) USPI EU-SmPC If needed USPI CCDS EU-SmPC Close(r) to submission 20 10
11 Topics: Various Core Labeling used during Clinical Development and their interrelationships How early to start and how and when to transition to core labeling for a development product Benefits of applying the principles of core labeling during clinical development Drug Information Association 21 Benefits of applying the principles of core labeling during clinical development Promote consistency in decision making across the development and marketing phases Identify gaps in development plan through Internal discussion Interaction with HAs Start early that you can influence the design of phase 3 trials and their statistical analysis Can be used for different target claims (indications), different audiences, and for different purposes Drug Information Association
12 Benefits of applying the principles of core labeling during clinical development - continued In addition to Core content, also prepare anticipated national deviations (content and wording), e.g., ADR section Drug Information Association 23 Questions? Drug Information Association
Procedures in Regard to Entire Product Information Dr. Klaus Menges BfArM Bethesda (MD) October 14, 2011
Harmonization of Labeling Across Products with Same Active Moiety in the EU Procedures in Regard to Entire Product Information Texts Dr. Klaus Menges BfArM Bethesda (MD) October 14, 2011 Disclaimer The
More informationPharmacovigilance in Asia: The China Perspectives. Disclaimer
Pharmacovigilance in Asia: The China Perspectives Rebecca Wang, MD, FRCP, FACC Head, Product Development Drug Safety Operation, Asia Pacific Roche Shanghai Disclaimer The views and opinions expressed in
More informationFDA Requirements 5/16/2011. FDA and new IND regs. Changes on the horizon: CIOMS IX ICH upcoming initiatives
Session Overview (1) Although the role of the Qualified Person responsible for Pharmacovigilance is mandated by the European legislation, the QPPV is held responsible for the establishment and the maintenance
More informationStructured Content Management [SCM]
Structured Content Management [SCM] Lessons learned from SCM implementations Shailesh Shah ArborSys Group Ole Rom Andersen CEO, DITA Exchange Inc. The views and opinions expressed in the following PowerPoint
More informationConstructing an etmf 12/2/2011. consider your current etmf structure!! The do s and don ts of EDM. Disclaimer
Constructing an etmf The do s and don ts of EDM Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug
More informationEffective application of Risk Management techniques to Drug Safety: a pragmatic approach
Effective application of Risk Management techniques to Drug Safety: a pragmatic approach Dr Mark Perrott WCI Consulting ltd 19th October 2009 1 Disclaimer The views and opinions expressed in the following
More informationQPPV Association and Training Part 2 Session Introduction
QPPV Association and Training Part 2 Session Introduction Steve Douglas QPPV SGD Consulting Limited PrimeVigilance Ltd Disclaimer The views and opinions expressed in the following PowerPoint slides are
More informationProject Management Standards Applied to Complex Clinical Trials. Disclaimer
Project Management Standards Applied to Complex Clinical Trials Alexander Gissler, PMP ProjectPharm Ltd., Owner & Director 1 Disclaimer The views and opinions expressed in the following PowerPoint slides
More informationAgency and Internal Labeling
Agency and Internal Labeling Audits Joseph McMillian, MA Heartland Compliance Services LLC Internal Labeling Audits The views and opinions expressed in the following PowerPoint slides are those of the
More informationUpdate on New MedDRA SOC Product issues
Update on New MedDRA SOC Product issues Judy Harrison, M.D. Chief Medical Officer, MedDRA MSSO ICSR Information Day 26 April 2016 London, UK Disclaimer The views and opinions expressed in the following
More informationThe views and opinions expressed in the following PowerPoint slides are
Indications, Dosage and Administration, Clinical Studies, Clinical Pharmacology sections of a CCDS Presented by: Mary Jane Boyle Head, Worldwide Product Labeling Merck & Co., 13-October-2011 The views
More informationPromotional Materials. System Approach. Katie O Brien Associate Senior Consultant Global Quality Systems Eli Lilly and Company
Promotional Materials and a Quality Management System Approach Katie O Brien Associate Senior Consultant Global Quality Systems Eli Lilly and Company Disclaimer The views and opinions expressed in the
More informationSPL Use Case: Improving Compliance, Increasing Efficiencies, and Reducing Costs
SPL Use Case: Improving Compliance, Increasing Efficiencies, and Reducing Costs Doris Sincak Project Supervisor Sanofi Disclaimers DIA The views and opinions expressed in the following PowerPoint slides
More informationEugène van Puijenbroek, MD, PhD
Signal detection and signal management at the Netherlands Pharmacovigilance il Centre EudraVigilance Information Day 1 July 2009 Eugène van Puijenbroek, MD, PhD Disclaimer The views and opinions expressed
More informationHigh Quality or Poor Quality DB
The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers,
More informationDelivering GxP compliant mobile applications a practical case study. Presented by: Mark Stevens
Delivering GxP compliant mobile applications a practical case study Presented by: Mark Stevens Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual
More informationThe views and opinions expressed in the following PowerPoint slides are
Expedited Reporting of Important Changes to Foreign Safety Labeling and Expected Collaboration among Companies in Japan Rie Matsui, RPh Senior Manager, Post Marketing Regulatory Strategy, Pfizer Japan
More informationDocument Reuse: Theory and Practice
Document Reuse: Theory and Practice Peggy Boe, RN Sr. Director, Medical Writing Image Solutions, Inc (ISI) Company logo here Best Practice: Single Sourcing Creating reusable text and information Requires
More informationectd: A Clinical Reviewer s Experience Sarah M. Connelly, MD Medical Officer Division of Antiviral Products FDA
ectd: A Clinical Reviewer s Experience Sarah M. Connelly, MD Medical Officer Division of Antiviral Products FDA Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationSharing Regulatory Intelligence: Best Practices and Case Studies
Sharing Regulatory Intelligence: Best Practices and Case Studies Carolyn Hynes Sr. Director, Global Regulatory Intelligence, GlaxoSmithKline 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria
More informationHands-on in Latin America Regulations for Clinical Trials
Hands-on in Latin America Regulations for Clinical Trials Director: Silvia Zieher VP Clinical Development, Latin America Operations INC Research Disclaimer The views and opinions expressed in the following
More informationHow can Regulatory Agencies leverage the effectiveness of the Clinical Trials Enterprise
How can Regulatory Agencies leverage the effectiveness of the Clinical Trials Enterprise 10 th Latin American Conference on Clinical Research, October 2013 Xavier Luria, MD Drug Development and Regulation
More informationWhat is an ideal PSUR? A new focus based on aligned expectations
What is an ideal PSUR? A new focus based on aligned expectations Margarida Guimarães PRAC Member INFARMED, I.P. Periodic Safety Update Report Information Day 28 October 2016 London, UK Disclaimer The views
More informationPharmacovigilance Post July 2012 The new frontier
Pharmacovigilance Post July 2012 The new frontier Colleen Walsh Head, Safety and Benefit Risk Management Quality, Biogen Idec 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The
More informationIncorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance
Incorporating Risk- Based Monitoring Strategies: Challenges in Implementation Sherri Hubby, Director, U.S. Quality Assurance 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria. Disclaimer The
More informationInto the Clouds. Understanding How Cloud Computing Will Effect the Future of Regulated Content Management. Jennifer Goldsmith
Into the Clouds Understanding How Cloud Computing Will Effect the Future of Regulated Content Management Jennifer Goldsmith Vice President, Veeva Vault Veeva Systems The views and opinions expressed in
More informationesource What EDC Should Be Presenter: Ed Seguine President
esource What EDC Should Be Presenter: Ed Seguine President The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug
More informationDo Niche CROs have a Role in Drug Development?
Do Niche CROs have a Role in Drug Development? Dr Nermeen Varawalla, MD, DPhil (Oxon), MBA President & CEO ECCRO 1 Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationNew Regulation in Japan and Future Direction of PMDA. Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)
New Regulation in Japan and Future Direction of PMDA Tatsuya Kondo, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed in the following
More informationManaging Core Safety Information. Rob Begnett
Managing Core Safety Information Rob Begnett The views expressed in this presentation are my own and do not represent my employer nor legal advice on practice. Some definitions RSI Reference Safety Information
More informationLabelling & Naming. European Biosimilars Group (EBG) perspective. >400 Million patient days worldwide clinical experience with EU biosimilar medicines
Labelling & Naming European Biosimilars Group (EBG) perspective >400 Million patient days worldwide clinical experience with EU biosimilar medicines Elke Grooten, Director Public Affairs Sandoz Europe
More informationCMC Workshop CMC Challenges in Japan. April Bethesda, MD. Yoshihiro Matsuda, Ph.D., PMDA Session 10
CMC Workshop 2015 April 13-15 Bethesda, MD CMC Challenges in Japan Yoshihiro Matsuda, Ph.D., PMDA Session 10 Disclaimer The views and opinions expressed in the following PowerPoint slides are those of
More informationPMDA Update. - New Regulation in Japan and Future Direction of PMDA
PMDA Update - New Regulation in Japan and Future Direction of PMDA Kazuhiro SHIGETO, M.D., M.P.H., Ph.D. Executive Director, Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and
More informationPanama City, Panama April, 12-15, Marcelo Mario Matos Moreira. The Brazilian Health Surveillance Agency (ANVISA)
DIA Latin American Regulatory Conference Panama City, Panama April, 12-15, 2011 Biosimilars/Biotechnology Marcelo Mario Matos Moreira Coordinator Office of Biological Products The Brazilian Health Surveillance
More informationHow to successfully Implement and Leverage the Regulatory Intelligence Function
How to successfully Implement and Leverage the Regulatory Intelligence Function Marianne Koehne EU RI Network Group; Global RI Manager Boehringer Ingelheim 26th Annual EuroMeeting 25-27 March 2014 ACV,
More informationEARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS
EARLY DRUG DEVELOPMENT CONSULTANCY & SERVICES CLINICAL RESEARCH SOLUTIONS As a full service contract research organisation performing phase I to IV clinical trials across Europe and the Americas for 40
More informationfocus Pharmacovigilance Focus
focus 2 Pharmacovigilance Is there a difference in perceived practices between innovative and generic industries? Part 1: Analysis of spontaneous reporting practices in innovative and generic companies
More informationRevision of the Variations Regulation. Key Principles and Guidelines Development CONTENT
DIA/EMEA/CMD(h) Conference London 26 October 2009 Revision of the Variations Regulation - Key Principles and Guidelines Development Hilde Boone EMEA 1 1 CONTENT 1. Background & revision status 2. Types
More informationTransforming Regulatory Affairs through Technology - End to End Tech Platform Approach
Transforming Regulatory Affairs through Technology - End to End Tech Platform Approach Peter Lassoff, PharmD, FTOPRA VP & Head, Global Regulatory Affairs IQVIA Disclaimer The views and opinions expressed
More informationAndrew Williams Senior Director European Medical Operations GlaxoSmithKline Company logo here. Disclaimer
Fit for the future - A new strategic approach to Medical Information management within GSK Andrew Williams Senior Director European Medical Operations GlaxoSmithKline Company logo here 1 Disclaimer The
More informationTHE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS
THE BIOSIMILARS LANDSCAPE: STRATEGIES FOR CLINICAL AND COMMERCIAL SUCCESS What all developers need to know Alicia Baker Director, Global Regulatory Affairs Strategy, Covance John Carlsen, MHA Vice President,
More informationCurrent Regulatory Considerations and Challenges for Continuous Manufacturing of Pharmaceuticals
15th DIA Japan Annual Meeting 2018 Promoting Better Collaboration to Drive Global Health and Innovation in an Era of Medical and Scientific Transformation November 11-13, 2018 Tokyo Big Sight V5-S3 Current
More informationEffective Project Leadership and Management: Disclaimer
Effective Project Leadership and Management: A CRO Perspective Nita Ichhpurani, B.S., PMP Director, Drug Development Disclaimer The views and opinions expressed in the following PowerPoint slides are those
More informationGeneral Manager IST GmbH - Mannheim. 26th Annual EuroMeeting March 2014 ACV, Vienna Austria
EDC-System Selection From the point of view of small to mid-size CROs Steffen König General Manager IST GmbH - Mannheim 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The views
More informationNAS and KAS Industry perspective
NAS and KAS Industry perspective Henk Schuring Group Vice President Regulatory Affairs Europe Genzyme Europe BV, Netherlands 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria Disclaimer The
More information1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org December 28, 2010 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More informationQbD Approach and Regulatory Challenges in Japan
QbD Approach and Regulatory Challenges in Japan YOSHIHIRO MATSUDA Ph.D. Deputy Division Director Pharmaceuticals and Medical Devices Agency (PMDA) 26th Annual EuroMeeting 25-27 March 2014 ACV, Vienna Austria
More informationPMDA Town Hall. Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA)
PMDA Town Hall - New Regulation in Japan and Future Direction of PMDA Tatsuya KONDO, M.D., Ph.D. Chief Executive Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions expressed
More informationUsing etechnologies to Increase Efficiency and Quality in Regulatory Operations
Using etechnologies to Increase Efficiency and Quality in Regulatory Operations Tim Powell Submissions Management Global Regulatory Affairs Disclaimer The views and opinions expressed in the following
More informationRe: Docket No. FDA-2015-D-4562: Draft Guidance Safety Assessment for IND Safety Reporting
February 16, 2016 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2015-D-4562: Draft Guidance Safety Assessment for IND
More informationUtilities and Pitfalls of Modeling & Simulation in Pivotal Trials
Utilities and Pitfalls of Modeling & Simulation in Pivotal Trials H.M. James Hung, Ph.D Div. of Biometrics I, OB/OTS/CDER U.S. Food and Drug Administration Presented in PhRMA/FDA Workshop, October 28,
More informationDevelopment Safety Update Report Guidance
Development Safety Update Report Guidance This document provides instructions for the preparation and submission of a Development Safety Update Report (DSUR) for a Clinical Trial of an Investigational
More informationInterdisciplinary Perspectives on Development of Naming Standards for Biosimilar Medicines
Interdisciplinary Perspectives on Development of Naming Standards for Biosimilar Medicines Richard Dolinar, MD Chairman, Alliance for Safe Biologic Medicines Disclaimer The views and opinions expressed
More informationRegulatory Experience for a Gene Therapy Product in a Large Phase II European Study. Disclaimer
Regulatory Experience for a Gene Therapy Product in a Large Phase II European Study Catherine Mathis Director of Regulatory Affairs transgene 1 Disclaimer The views and opinions expressed in the following
More informationCurrent Challenges of Regulation in Japan - Amendment of Pharmaceutical Affairs Act
Current Challenges of Regulation in Japan - Amendment of Pharmaceutical Affairs Act Hiroshi Yamamoto, MS Chief Safety Officer Pharmaceuticals and Medical Devices Agency (PMDA), Japan 26th Annual EuroMeeting
More informationPost Marketing PV AUDIT AND INSPECTION HOSTING. Michael Ramcharan Reumat Consulting Ejaz Butt ZigZag Associates
Post Marketing PV AUDIT AND INSPECTION HOSTING Michael Ramcharan Reumat Consulting Ejaz Butt ZigZag Associates Agenda Background Preparation Conduct Post Audit & Inspection CAPA Management Audit & Inspection
More informationData standardization and advancing regulatory science
Data standardization and advancing regulatory science Yoshiaki Uyama, Ph.D. Pharmaceuticals & Medical Devices Agency (PMDA) Visiting Professor, Graduate School of Medicine, Chiba University Visiting Professor,
More informationClinical Documentation supporting Core Labels for Generics/OTC products
GLOBAL REGULATORY SOLUTIONS & SERVICES AN ISO 9001 & 27001 COMPANY Clinical Documentation supporting Core Labels for Generics/OTC products REGULATORY CONSULTING SUBMISSIONS AFFAIRS OUTSOURCING INTELLIGENCE
More informationThe Patient-Reported Outcome (PRO) Consortium:
The Patient-Reported Outcome (PRO) Consortium: A Collaborative Approach to PRO Instrument Development and Qualification Stephen Joel Coons, PhD Executive Director The views and opinions expressed in the
More informationSession 7 Clinical Trial Assessment Bioequivalence Studies
L1 Session 7 Clinical Trial Assessment Bioequivalence Studies Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager, Clinical Group I Office
More informationRegulatory perspective to review MRCT data for drug approval: Focusing on ethnic factor evaluation
Regulatory perspective to review MRCT data for drug approval: Focusing on ethnic factor evaluation Dr Yoshiaki Uyama Pharmaceuticals and Medical Devices Agency (PMDA) 1 Disclaimer The views and opinions
More informationSimilarity Assessment of Biosimilars. The Past, Present and Future State. Joseph Glajch, Ph.D and Jim Anderson, Ph.D Jan 28, 2016
Similarity Assessment of Biosimilars. The Past, Present and Future State Joseph Glajch, Ph.D and Jim Anderson, Ph.D Jan 28, 2016 Disclaimer The views and opinions expressed in the following PowerPoint
More informationHuman Vss Prediction. James Yates AstraZeneca. Disclaimer 10/25/2011
0/25/20 Human Vss Prediction Part 2: Comparative Assessment of Prediction Methods of Human Volume of Distribution R.D.O JONES,H.M. JONES, M. ROWLAND, C.R. GIBSON, J.W.T. YATES, J.Y. CHIEN, B. J. RING,
More informationModeling and Simulation for Dose Selection using Adaptive Designs
Modeling and Simulation for Dose Selection using Adaptive Designs Nitin Patel Chairman and C.T.O. Cytel, Inc. Disclaimer The views and opinions expressed in the following PowerPoint slides are those of
More informationCDER Perspective: Good Clinical Practice
CDER Perspective: Good Clinical Practice Sensible Guidelines Symposium, 25 May 2012 Ann Meeker-O Connell FDA, CDER, Office of Compliance Office of Scientific Investigations The views presented in this
More informationPMDA Perspectives on Companion Diagnostics Development in Japan. Reiko Yanagihara, Ph.D. Deputy Review Director Office of In Vitro Diagnostics, PMDA
PMDA Perspectives on Companion Diagnostics Development in Japan Reiko Yanagihara, Ph.D. Deputy Review Director Office of In Vitro Diagnostics, PMDA 1 Disclaimer Content Slide The views and opinions expressed
More informationHTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned?
HTAs and EMA working together: 23 parallel scientific advice procedures later - what have we learned? DIA 26th Annual EuroMeeting, Vienna 2014 Jan Regnstrom, MD, PhD Senior Scientific Officer An agency
More informationTrial Master File Reference Model. Project Charter. Review, Testing, and Ratification of the etmf Exchange Mechanism Standard, Version 1
Trial Master File Reference Model Project Charter Review, Testing, and Ratification of the etmf Exchange Mechanism Standard, Version 1 Prepared by The Exchange Mechanism Standard Subgroup of the TMF Reference
More informationThe Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports
The Safety Case as a basis for more effective outsourcing of writing of aggregate safety reports Dr Brian Edwards Scientific Adviser, Pharmacovigilance & Drug Safety, NDA Regulatory Science Ltd DIA 3rd
More informationProject Management Competencies. Disclaimer 28/06/2011
Project Management Competencies Martin D. Hynes III, Ph.D. Senior Director Product Research & Development Lilly Research Laboratories Eli Lilly and Company Indianapolis, IN Disclaimer The views and opinions
More informationGuidelines for Setting Up a Regulatory Binder
Guidelines for Setting Up a Regulatory Binder Prepare for an audit Georgamaly Estronza, MS UPR - Medical Sciences Campus IRB Administrator - Compliance Officer Email: georgamaly.estronza@upr.edu Introduction
More informationPharmaSUG 2012 Paper #IB01
PharmaSUG 2012 Paper #IB01 Adapt and Survive: Implementing the new ICH Development Safety Update Report (DSUR) Patricia L. Gerend, Genentech Inc., South San Francisco, CA Rajkumar Sharma, Genentech Inc.,
More informationINTRODUCTION TO PHARMACOVIGILANCE AND REGULATORY AFFAIRS SPRING 2012
INTRODUCTION TO PHARMACOVIGILANCE AND REGULATORY AFFAIRS SPRING 2012 Course Description: Pharmacovigilance is the science and activities that relate to the detection, monitoring, assessment, understanding
More informationInternational Transfers of Personal Data at sanofi-aventis R & D
International Transfers of Personal Data at sanofi-aventis R & D Pierre-Yves Lastic, PhD Senior Director, Standards Management & Data Privacy Sanofi-aventis R&D CONFERENCE ON INTERNATIONAL TRANSFERS OF
More informationClinical trial applications in the EU and US
Clinical trial applications in the EU and US Alain Patat, M.D. Translational Development Wyeth Research Paris, France AGAH-Club Phase 1 1 st Symposium Strasbourg 17-18 March 2005 Overview of the presentation
More informationPOST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312)
POST-IRB APPROVAL FDA DRUG (IND) SPONSOR AND INVESTIGATOR RESPONSIBILITY (21 CFR312) Purpose: Investigators who initiate and submit an IND application to the FDA assume the responsibilities of both the
More informationDevelopment of Orphan Drugs Regulatory Viewpoints from PMDA
Development of Orphan Drugs Regulatory Viewpoints from PMDA Ken Sakushima Office of Cellular and Tissue-based Products, Office of New Drug III Pharmaceuticals and Medical Devices Agency (PMDA) Disclaimer
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More informationInterdependencies of Pharmacovigilance and Regulatory Affairs
Lorenz userbridge 2013 Budapest, September 17th Interdependencies of Pharmacovigilance and Regulatory Affairs Dr. rer. nat. Markus Dehnhardt Deputy QPPV Biologist Toxicologist Medical advisor Agenda 1.
More informationIntroduction of OTC switch in China. Han Qing Regulatory Affairs of One China OTC J&J Oct
Introduction of OTC switch in China Han Qing Regulatory Affairs of One China OTC J&J Oct 22 2014 Outline Regulatory History Classification Switch Challenges Regulatory History 3 stages Stage 1: before
More informationSafety Reporting Part 1: For Clinical Trials of Investigational Medicinal Products (CTIMPs)
Part 1: For Clinical Trials of Investigational Medicinal Products (CTIMPs) Version 1.4 Effective date: 1 December 2011 Author: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision
More informationVM-ID: MU101_20_001e_WL - Wegleitung_HD - Hilfsdokument / V3.0 / dst / er / / 6
Contents 1 Abbreviations... 1 2 Requirements for signal reports... 2 3 Introduction... 2 4 Objective... 2 5 Scope... 2 6 Company signals (signals evaluated by the MAH)... 2 6.1 Signals involving a serious
More informationEMEA Speaker Brief Page 1
EMEA SPEAKER BRIEF Commitment to ethics and integrity Bristol-Myers Squibb (BMS) is committed to the highest standards of ethics and integrity and recognises the high expectations of honesty and transparency
More informationHow to put together an IND application
How to put together an IND application Judit Milstein, Chief, Project Management Staff Judit.milstein@fda.hhs.gov Eithu Lwin, Regulatory Health Project Manager Eithu.Lwin@fda.hhs.gov Division of Transplant
More informationQbD approach and Regulatory Challenges in Europe
QbD approach and Regulatory Challenges in Europe DIA 26th Annual EuroMeeting, Vienna 2014 Dr Peter Richardson Head of Quality, European Medicines Agency An agency of the European Union Disclaimer The views
More informationPlanning of Application
2016 Good Registration Management Regulatory Science Center of Excellence Pilot Workshop Planning of Application Moderator: Speaker: Jin Shun, AbbVie Thean Soo Lo, J&J Sannie Chong, Roche Agenda 10:00~10:05
More informationStandard Operating Procedure (SOP) Research and Development Office
Standard Operating Procedure (SOP) Research and Development Office Title of SOP: Creation & Maintenance of an Investigator Brochure SOP Number: 34 Version Number: 1.0 Supercedes: N/A Effective date: August
More informationIntegrated Content Management
Integrated Content Management Ikram Baig Chief Technology Officer Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be
More informationRe: Docket No. FDA-2008-D-0386: International Conference on Harmonisation; Draft Guidance on E2F Development Safety Update Report; Availability.
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org November 03, 2008 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More informationManagement and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility
Management and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility Document Detail Document type Standard Operating Procedure CRF-STU-SOP-1: Management and Accountability
More informationEffective Date: October 8, 2015 Policy Number: MHC_RP0301. Corporate Director, HRPP Institutional Official, HRPP
Policy Title: Education and Quality Improvement Program EQuIP Effective Date: October 8, 2015 Policy Number: Review Date: October 8, 2015 Section: Revised Date: Administrative Responsibility: Oversight
More informationConducted Under an IND to Support a
Using Foreign Clinical Trial Data not Conducted Under an IND to Support a US Application PDA Midwest Chapter Meeting March 15, 2018 2013 2017 Regulatory Compliance Associates Inc. All Rights Reserved.
More informationManagement and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility
Management and Accountability of Investigational Medicinal Products in the King s Clinical Research Facility Document Detail Document type Standard Operating Procedure CRF-STU-SOP-1: Management and Accountability
More informationPerformance Based Regulatory Assessment
Performance Based Regulatory Assessment Leveraging the Depth of Industry Knowledge with the Breadth of Regulator Knowledge FDA/PQRI Conference 6 October 2015 Bethesda, MD roger nosal Vice President & Head
More informationPolicy Appendix IV: DRCR.net Industry Collaboration Policies Version 6.0, August 2, 2017
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 DRCR.net is committed to: performing rigorous multi-center clinical
More informationSupply of IND Agents to Multi-center trials by Skilled Academic Sites
Supply of IND Agents to Multi-center trials by Skilled Academic Sites Paula M. Jacobs, Ph.D. Associate Director, Division of Cancer Treatment and Diagnosis, NCI Cancer Imaging Program June 2016 SNMMI San
More informationClinical Research with Drugs/Biologics and Devices & Good Clinical Practices
Clinical Research with Drugs/Biologics and Devices & Good Clinical Practices Jason Jobson, BLS, CCRP Research Compliance Officer Oklahoma City VA Medical Center October 2017 Goals Investigational New Drug
More informationCompliance & Validation Validation of Software-as-a-Service (SaaS Solutions)
www.arisglobal.com A White Paper Presented By ArisGlobal Compliance & Validation Validation of Software-as-a-Service (SaaS Solutions) ARIS GLOBAL CORPORATE HEADQUARTERS ArisGlobal, 1266 East Main Street,
More informationHow did it evolve? o Public disasters, serious fraud and abuse of human rights. o Trials of War criminals-nuremberg code 1949
ICH GCP Overview What is ICH? ICH is a joint initiative involving both the regulators and the industry as equal partners in the scientific and technical discussions of the testing procedures which are
More information